1. P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211). (23rd June 2022) Authors: Usmani, S.; Hoering, A.; Ailawadhi, S.; Sexton, R.; Lipe, B.; Valent, J.; Rosenzweig, M.; Zonder, J.; Dhodapkar, M.; Callander, N.; Zimmerman, T.; Voorhees, P.; Durie, B.; Rajkumar, S. V.; Richardson, P.; Orlowski, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 855 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202. (23rd June 2022) Authors: Voorhees, P.; Suman, V.; Efebera, Y.; Raje, N.; Tuchman, S.; Rodriguez, C.; Santo, K.; Bova-Solem, M.; Carlisle, D.; Saad, U.; McCarthy, P.; Richardson, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 858 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗